Retractable Technologies, Inc.
RVP Healthcare Medical Instruments & Supplies
Retractable Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.3 million, up 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 31.1%, EPS was flat, free cash flow grew 56.7% and total debt fell 32.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow RVP
Retractable Technologies, Inc. (RVP) EV/Sales
As of 16 October 2026, Retractable Technologies, Inc. (RVP) trades at a EV/Sales of −0.6×. Over the past ten years it has ranged from −0.7× (December 2024) to 8.9× (July 2020); the current reading is higher than 0% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.3× | — |
| FY2024 | −0.7× | — |
| FY2023 | −0.3× | — |
| FY2022 | 0.1× | (92.62%) |
| FY2021 | 1.0× | (74.61%) |
| FY2020 | 3.9× | 334.08% |
| FY2019 | 0.9× | 201.66% |
| FY2018 | 0.3× | 0.33% |
| FY2017 | 0.3× | (44.79%) |
| FY2016 | 0.5× | (77.67%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −0.5× | — |
| Mar 2026 | −0.4× | — |
| Dec 2025 | −0.3× | — |
| Sep 2025 | −0.2× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RVP Retractable Technologies, Inc. | −0.6× |
| RGNT Regentis Biomaterials Ltd. compare | n/m |
| CUPR Cuprina Holdings (Cayman) Limited compare | n/m |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| HBIO Harvard Bioscience, Inc. compare | 1.1× |
| NEPH Nephros Inc. compare | 1.7× |
| MLSS Milestone Scientific, Inc. compare | 3.1× |
| FEMY Femasys Inc. compare | 3.4× |
| NXGL NexGel, Inc. compare | 4.3× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)